Key Benefits

• No dose adjustment is required for Patients with impaired liver function
  
  
• Immediate release film-coated tablet for oral administration
  
  
• It inhibits bacterial DNA replication, transcription, repair and recombination.
  
  
• The absolute bioavailability is approximately 70 80%.
  
  
  

Indications

     Adults

• Lower respiratory tract infections due to Gram-negative bacteria
  
  
• exacerbations of chronic obstructive pulmonary disease
  
  
• broncho-pulmonary infections in cystic fibrosis or in bronchiectasis
  
  
• Pneumonia
  
  
• Chronic suppurative otitis media
  
  
• Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria
  
  
• Urinary tract infections
  
  
• Gonococcal uretritis and cervicitis
  
  
• Epididymo-orchitis including cases due to Neisseria gonorrhoeae
  
  
• Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae
  
  
• Infections of the gastro-intestinal tract (e.g. travellers' diarrhoea)
  
  
• Intra-abdominal infections
  
  
• Infections of the skin and soft tissue caused by Gram-negative bacteria
  
  
• Malignant external otitis
  
  
• Infections of the bones and joints
  
  
• Prophylaxis of infections in neutropenic patients
  
  
• Prophylaxis of invasive infections due to Neisseria meningitides
  
  
• Inhalation anthrax (post-exposure prophylaxis and curative treatment)
  
  Children
  
  
• Broncho-pulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa
  
  
• Complicated urinary tract infections and pyelonephritis
  
  
• Inhalation anthrax (post-exposure prophylaxis and curative treatment)